pylclari
curium pet france - piflufolastat (18f) - prostata neoplasmer - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).
veraseal
instituto grifols, s.a. - human fibrinogen, human trombin - hemostase, kirurgisk - antihemoragika - støttende behandling i voksne der standard kirurgiske teknikker er ikke nok:for forbedring av haemostasisas sutur støtte i karkirurgi.
zoladex 3.6 mg
astrazeneca - goserelinacetat - implantat - 3.6 mg
zoladex 10.8 mg
astrazeneca - goserelinacetat - implantat - 10.8 mg
zoladex 3.6 mg
orifarm as - goserelinacetat - implantat - 3.6 mg
zoladex 3.6 mg
orifarm as - goserelinacetat - implantat - 3.6 mg
zoladex 3.6 mg
orifarm as - goserelinacetat - implantat - 3.6 mg
zoladex 3.6 mg
orifarm as - goserelinacetat - implantat - 3.6 mg
zoladex 10.8 mg
orifarm as - goserelinacetat - implantat - 10.8 mg
zoladex 10.8 mg
orifarm as - goserelinacetat - implantat - 10.8 mg